[go: up one dir, main page]

UA116915C2 - Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter - Google Patents

Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter

Info

Publication number
UA116915C2
UA116915C2 UAA201604997A UAA201604997A UA116915C2 UA 116915 C2 UA116915 C2 UA 116915C2 UA A201604997 A UAA201604997 A UA A201604997A UA A201604997 A UAA201604997 A UA A201604997A UA 116915 C2 UA116915 C2 UA 116915C2
Authority
UA
Ukraine
Prior art keywords
antigenic peptide
vector coding
campylobacter infections
improving influence
campylobacter
Prior art date
Application number
UAA201604997A
Other languages
English (en)
Inventor
Біллі Харджис
Нейл Р. Памфорд
Янг Мін Квон
Шеррілл Лейтон
Original Assignee
Дзе Борд Оф Трастіз Оф Дзе Юніверсіті Оф Арканзас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Борд Оф Трастіз Оф Дзе Юніверсіті Оф Арканзас filed Critical Дзе Борд Оф Трастіз Оф Дзе Юніверсіті Оф Арканзас
Publication of UA116915C2 publication Critical patent/UA116915C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід стосується вектора, що кодує антигенний пептид (cjaA, cj0982), та фармацевтичної композиції, яка його включає. Винахід також стосується способу посилення імунної відповіді у пацієнта, способу підвищення стійкості до інфекції, що викликається Campylobacter, що включає введення пацієнту даного вектора.
UAA201604997A 2010-06-09 2011-06-09 Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter UA116915C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35303910P 2010-06-09 2010-06-09
UAA201300278A UA113496C2 (xx) 2010-06-09 2011-06-09 Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter

Publications (1)

Publication Number Publication Date
UA116915C2 true UA116915C2 (uk) 2018-05-25

Family

ID=45098670

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201300278A UA113496C2 (xx) 2010-06-09 2011-06-09 Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter
UAA201604997A UA116915C2 (uk) 2010-06-09 2011-06-09 Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201300278A UA113496C2 (xx) 2010-06-09 2011-06-09 Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter

Country Status (23)

Country Link
US (2) US8961990B2 (uk)
EP (2) EP2579901B1 (uk)
JP (1) JP5746333B2 (uk)
KR (3) KR102008120B1 (uk)
CN (1) CN102971008B (uk)
AR (1) AR081856A1 (uk)
AU (3) AU2011264772B2 (uk)
BR (1) BR112012031211A2 (uk)
CA (1) CA2800830C (uk)
CL (1) CL2012003458A1 (uk)
CO (1) CO6670521A2 (uk)
DK (1) DK2579901T3 (uk)
EA (1) EA030793B1 (uk)
ES (1) ES2753142T3 (uk)
HU (1) HUE046858T2 (uk)
MX (2) MX377650B (uk)
NZ (3) NZ702839A (uk)
PH (1) PH12012502428B1 (uk)
PL (1) PL2579901T3 (uk)
PT (1) PT2579901T (uk)
UA (2) UA113496C2 (uk)
WO (1) WO2011156619A2 (uk)
ZA (1) ZA201209411B (uk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
US9603915B2 (en) 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
US20150044698A1 (en) * 2013-08-06 2015-02-12 Techlab, Inc. Outer membrane protein 18 as a diagnostic marker for campylobacter
US20170196971A1 (en) * 2014-06-05 2017-07-13 The Board Of Trustees Of The University Of Arkansas Antibody guided vaccines and methods of use for generation of rapid mature immune responses
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105223362B (zh) * 2015-09-10 2016-08-31 上海慧耘生物科技有限公司 空肠弯曲菌酶联免疫检测试剂盒
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL170938B1 (pl) 1991-03-05 1997-02-28 Wellcome Found Sposób wytwarzania szczepionki przeciwko infekcjom Salmonella PL PL
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
CA2121798C (en) 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
CA2143299A1 (en) 1992-09-04 1994-03-17 Brenda J. Allan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
NZ305083A (en) 1995-03-01 1999-06-29 Immunex Corp Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
CA2222914C (en) 1995-06-07 2002-04-02 Immunex Corporation Novel cd40l mutein
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
CA2313805A1 (en) 1997-12-19 1999-07-01 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
CA2341349C (en) 1998-09-04 2013-12-10 Creatogen Aktiengesellschaft Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
JP2000351735A (ja) * 1999-04-09 2000-12-19 Akzo Nobel Nv カンピロバクターワクチン
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
JP2003508016A (ja) 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
US7118751B1 (en) 1999-10-14 2006-10-10 Trubion Pharmaceuticals, Inc. DNA vaccines encoding antigen linked to a domain that binds CD40
PT1112747E (pt) 1999-12-28 2004-10-29 Akzo Nobel Nv Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
CA2399790C (en) 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus
NZ521425A (en) 2000-03-17 2004-05-28 Upjohn Co Vaccine comprising a first attenuated non-reverting mutant Salmonella in which two or more secretion system apparatus genes have been inactivated
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
WO2002000232A2 (en) 2000-06-26 2002-01-03 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
WO2002036769A2 (en) 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
HUP0500042A3 (en) 2001-05-15 2010-01-28 Long Island Jewish Res Inst Use of hmg fragments as anti-inflammatory agents
ES2329453T3 (es) 2001-05-15 2009-11-26 Ortho Mcneil Janssen Pharm Cebado ex-vivo para generar linfocitos t citotoxicos especificos del ligando cd40 para tratar enfermedades autoinmunitarias y alergicas.
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
WO2003051383A2 (de) 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
WO2003096812A1 (en) 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
AU2003295653B2 (en) 2002-11-20 2007-08-16 The Feinstein Institute Of Medical Research Use of HMGB polypeptides for increasing immune responses
NZ540067A (en) 2002-11-20 2007-05-31 Critical Therapeutics Inc A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
CN1906210A (zh) 2003-11-21 2007-01-31 Ace生物科学公司 表面定位的空肠弯曲杆菌多肽
CA2548347A1 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005103073A2 (en) * 2004-04-27 2005-11-03 Intercell Ag Td antigens
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
EP1814576A2 (en) 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
US20100040608A1 (en) 2005-07-18 2010-02-18 Marie Wahren-Herlenius Use of HMGB1 antagonists for the treatment of inflammatory skin conditions
DE602006014720D1 (de) 2005-10-07 2010-07-15 Proyecto Biomedicina Cima Sl Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
JP2009514536A (ja) 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター Ｃｄ４０リガンド融合蛋白質ワクチン
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US8802419B2 (en) * 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
WO2008008092A2 (en) 2006-07-10 2008-01-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter pilus protein, compositions and methods
JP2010500034A (ja) 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
ES2520026T3 (es) 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para potenciar respuestas inmunitarias
US20100292309A1 (en) 2007-03-08 2010-11-18 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
CN101969990B (zh) 2007-11-01 2014-07-09 阿肯色大学评议会 增强针对艾美球虫属的免疫反应的组合物和方法
CN101332304A (zh) * 2008-08-05 2008-12-31 扬州大学 一种空肠弯曲菌壳聚糖纳米dna疫苗及其制备方法和应用
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法

Also Published As

Publication number Publication date
KR102007132B1 (ko) 2019-08-05
AR081856A1 (es) 2012-10-24
NZ604412A (en) 2015-01-30
EP3556397A1 (en) 2019-10-23
JP5746333B2 (ja) 2015-07-08
PH12012502428B1 (en) 2019-01-23
AU2017202104B2 (en) 2018-08-23
EA030793B1 (ru) 2018-09-28
MX2012014395A (es) 2013-02-26
AU2011264772A1 (en) 2013-01-24
EP2579901A4 (en) 2013-11-06
KR101881611B1 (ko) 2018-07-25
CA2800830A1 (en) 2011-12-15
MX377650B (es) 2025-03-11
AU2015243062A1 (en) 2015-11-12
JP2013537401A (ja) 2013-10-03
MX350306B (es) 2017-09-04
US20150190496A1 (en) 2015-07-09
WO2011156619A3 (en) 2012-02-16
AU2015243062B2 (en) 2017-05-04
AU2011264772A2 (en) 2013-02-14
CN102971008A (zh) 2013-03-13
KR20180126618A (ko) 2018-11-27
ZA201209411B (en) 2015-05-27
KR102008120B1 (ko) 2019-08-07
AU2011264772B2 (en) 2015-07-16
CN102971008B (zh) 2015-11-25
EA201291373A1 (ru) 2013-05-30
UA113496C2 (xx) 2017-02-10
CA2800830C (en) 2020-09-08
PL2579901T3 (pl) 2020-02-28
PT2579901T (pt) 2019-11-05
NZ718006A (en) 2017-06-30
DK2579901T3 (da) 2019-11-04
EP2579901A2 (en) 2013-04-17
EP2579901B1 (en) 2019-08-07
US20130084304A1 (en) 2013-04-04
CO6670521A2 (es) 2013-05-15
KR20130088122A (ko) 2013-08-07
AU2017202104A1 (en) 2017-04-20
WO2011156619A2 (en) 2011-12-15
KR20180085064A (ko) 2018-07-25
US10960068B2 (en) 2021-03-30
NZ702839A (en) 2016-04-29
HUE046858T2 (hu) 2020-03-30
BR112012031211A2 (pt) 2018-01-30
ES2753142T3 (es) 2020-04-07
PH12012502428A1 (en) 2013-02-18
CL2012003458A1 (es) 2013-04-05
US8961990B2 (en) 2015-02-24

Similar Documents

Publication Publication Date Title
UA116915C2 (uk) Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter
MX2016002154A (es) Vacuna contra el virus respiratorio sincitial.
SG10201907522QA (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
IN2014DN09351A (uk)
EA202090699A3 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
MX361728B (es) Ácido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilación para incrementar la expresión de un antígeno tumoral codificado.
MX391136B (es) FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO
EA201890355A1 (ru) Новые способы индукции иммунного ответа
HK1225631A1 (zh) 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
MX2017016401A (es) Composiciones inmunogenas.
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
GB201118201D0 (en) Novel peptides
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
UA114298C2 (uk) Пептид торк та вакцина, що його містить
NZ700467A (en) Treatments suitable for malassezia infections
MY167069A (en) Antigen peptide and use thereof
WO2013084070A3 (en) Salmonella vaccine proteins
EP4461365A3 (en) Respiratory syncytial virus (rsv) vaccine
BR112013007308A2 (pt) vacina
MX350236B (es) Composiciones de peptidos para el tratamiento y diagnostico de la fiebre por virus del dengue.
UA106111C2 (uk) Спосіб отримання людського інтерферону з використанням наночастинок оксиду церію